Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Kisqali by Quarter
Kisqali — Number of Countries with Early Breast Cancer (eBC) Indication Approved
Novartis Kisqali: 84 in Q3 2026, up 50.0% from a year earlier.
Latest, Q3 2026
84
Period ended Sep 30, 2026
Change on a year earlier
+50.0%
56 in Q3 2025
History
5 quarters
Since Q3 2025
Sources
5
Documents cited below
Where the Q3 2026 figure comes from
“| approved in 84 countries and reimbursed in 43”
Source: Novartis Official IR / Sustainability Report — q3-2026-investor-presentation.pdf ↗
Reported in Quarterly Investor Presentations.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Kisqali — Number of Countries with Early Breast Cancer (eBC) Indication Approved | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 84 | +50.0% | Novartis Official IR / Sustainability Report — q3-2026-investor-presentation.pdf ↗ |
| Q2 2026 | Jun 30, 2026 | 76 | – | Novartis Official IR / Sustainability Report — q2-2026-investor-presentation.pdf ↗ |
| Q1 2026 | Mar 31, 2026 | 69 | – | Novartis Official IR / Sustainability Report — q1-2026-investor-presentation.pdf ↗ |
| Q4 2025 | Dec 31, 2025 | 62 | – | Novartis Official IR / Sustainability Report — q4-2025-investor-presentation.pdf ↗ |
| Q3 2025 | Sep 30, 2025 | 56 | – | Novartis Official IR / Sustainability Report — q3-2025-investor-presentation.pdf ↗ |
Cite this data
StockData. (2026). Novartis Kisqali, quarterly Q3 2025–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/rx-kisqali-ebc-approved-countries
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.